Anticancer activity of Araguspongine C via inducing apoptosis, and inhibition of oxidative stress, inflammation, and EGFR‐TK in human lung cancer cells: An in vitro and in vivo study

Abstract The advanced non‐small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutations has put a selective pressure on the discovery and development of newer EGFR inhibitors. Therefore, the present study intends to explore the pharmacological effect of Araguspongine C (Aragus‐C) as anticancer agent against lung cancer. The effect of Aragus‐C was evaluated on the viability of the A549 and H1975 cells. Further biochemical assays were performed to elaborate the effect of Aragus‐C, on the apoptosis, cell‐cycle analysis, and mitochondrial membrane potential in A549 cells. Western blot analysis was also conducted to determine the expression of EGFR in A549 cells. Tumor xenograft mice model from A549 cells was established to further elaborate the pharmacological activity of Aragus‐C. Results suggest that Aragus C showed significant inhibitory activity against A549 cells as compared to H1975 cells. It has been found that Aragus‐C causes the induction of apoptosis and promotes cell‐cycle arrest at the G2/M phase of A549 cells. It also showed a reduction in the overexpression of EGFR in A549 cells. In tumor xenograft mice model, it showed a significant reduction of tumor volume in a dose‐dependent manner, with maximum inhibitory activity was reported by the 8 mg/kg treated group. It also showed significant anti‐inflammatory and antioxidant activity by reducing the level of TNF‐α, IL‐1β, IL‐6, and MDA, with a simultaneous increase of superoxide dismutase and glutathione peroxidase. We have demonstrated the potent anti‐lung cancer activity of Aragus‐C, and it may be considered as a potential therapeutic choice for NSCLC treatment.